Copenhagen, Denmark, 2011-03-15 08:00 CET (GLOBE NEWSWIRE) --Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression
analysis products, today announced the launch of additional 235 pre-validated
miRCURY LNA™ Universal RT microRNA qPCR assays for sensitive and specific
quantification of microRNAs.

With the launch of the new assays, Exiqon now offers 1731 pre-validated qPCR
assays for human, mouse and rat microRNAs. In addition to the pre-validated
qPCR assays, Exiqon offers to custom design LNA™-enhanced qPCR assays for any
microRNA. The proprietary design software which is available on the company's
website, is based on an advanced design algorithm which applies more 60 design
parameters.

“With this launch, Exiqon offers the highest number of pre-validated assays for
human, mouse and rat microRNAs on the market”, said Vice President Sales &
Marketing, Dr. Henrik M. Pfundheller and added: “We have seen an increasing
demand for rodent microRNA assays - in particular for detection of microRNAs
from mouse serum/plasma samples. We are dedicated to developing and marketing
LNA™-enhanced microRNA qPCR products for new and challenging applications such
as serum and plasma analyses”.

Exiqon's product line for microRNA qPCR also includes ready-to-use panels for
genome-wide screening of human, mouse and rat microRNAs as well as RT and
Master Mix kits and a qPCR data analysis software.

Information about the miRCURY LNA™ microRNA qPCR products is available at
Exiqon's website: http://www.exiqon.com/qPCR.

Additional information:
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Henrik M. Pfundheller, VP Sales & Marketing, tel. +45 4565 0420 (cell: +45 4090
2106)

See the full release in the attached PDF or at www.exiqon.com/investor/portal.

PressRelease_qPCR_assays_110315.pdf